Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct 1, 2020 Jan 1, 2021 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
C9131 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jul 1, 2013 Dec 31, 2013 No Longer Used
J9309 Polatuzumab Vedotin Polivy 1mg Immunotherapy Drug Antibody Conjugate CD79b No 2019 Jan 1, 2020 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct 1, 2019 In Use
C9084 Loncastuximab tesirine Zylonta 0.1mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Sep 27, 2021 Mar 25, 2022 In Use
J9203 Gemtuzumab ozogamicin Mylotarg 0.1 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2018 In Use
C9004 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2004 Dec 31, 2005 No Longer Used
J9273 Tisotumab vedodin-tftv Tivdak 1mg Immunotherapy Drug Antibody Conjugate Tissue factor No 2021 Mar 25, 2022 In Use
J9359 Loncastuximab tesirine-lpyl Zynlonta 0.075mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Mar 25, 2022 In Use
J9354 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jan 1, 2014 In Use
J9300 Gemtuzumab ozogamicin Mylotarg 5 mg Immunotherapy Drug Antibody Conjugate CD33 No 2000 Jan 1, 2002 In Use
C9146 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
C9065 Romidepsin Romidepsin 1mg Chemotherapy Enzyme Inhibetor HDAC No 2020 Jan 1, 2021 Sep 27, 2021 No Longer Used
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
NA Selinexor Xpovio 20mg, 40mg, 50mg, 60mg Chemotherapy Enzyme Inhibitor XPO1 Yes 2019 In Use
NA Ruxolitinib Jakafi 25 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
Inavolisib Itovebi 3mg, 9mg Chemotherapy Enzyme Inhibitor PI3K⍺ Yes 2024 In Use
J7527 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2013 In Use
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2012 Dec 31, 2012 No Longer Used
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Panobinostat Farydak 20 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.